Aumolertinib Combined with Chemotherapy Enhances Progression-Free Survival in NSCLC Patients Harboring EGFR and Tumor Suppressor Gene Alterations: Findings from the ACROSS 2 Phase III Trial
Groundbreaking Phase III Trial Demonstrates Superior Efficacy of Aumolertinib Plus Chemotherapy in Advanced EGFR-Mutant NSCLC In a pivotal advancement for...